background
outcom
sever
human
metapneumoviru
hmpv
associ
pneumonia
adequ
evalu
object
aim
investig
incid
outcom
sever
hmpvassoci
cap
compar
sever
ifv
associ
cap
studi
design
march
august
consecut
adult
patient
sever
hmpvassoci
cap
sever
influenza
viru
ifv
associ
cap
requir
intens
care
unit
admiss
prospect
identifi
follow
tertiari
care
hospit
characterist
outcom
sever
hmpvassoci
cap
patient
compar
sever
ifvassoci
cap
patient
result
hmpv
ifv
identifi
patient
sever
cap
respect
mortal
rate
significantli
differ
hmpv
ifv
group
mortal
vs
p
mortal
vs
p
oral
ribavirin
therapi
associ
improv
outcom
mortal
ribavirin
therapi
group
vs
ribavirin
therapi
group
p
subgroup
analys
show
signific
differ
mortal
among
nonimmunocompromis
mortal
hmpv
vs
ifv
p
immunocompromis
patient
mortal
hmpv
vs
p
length
icu
hospit
stay
differ
group
conclus
incid
hmpv
infect
approxim
half
ifv
infect
cohort
patient
sever
cap
mortal
rate
sever
hmpvassoci
cap
similar
sever
ifv
associ
cap
adult
sever
hmpvassoci
communityacquir
pneumonia
cap
requir
intens
care
unit
icu
admiss
outcom
analys
prior
icu
studi
limit
retrospect
design
rel
small
number
patient
lack
adequ
control
group
heterogen
studi
popul
sinc
first
discoveri
human
metapneumoviru
hmpv
young
children
hmpv
recogn
import
agent
upper
lower
respiratori
tract
diseas
worldwid
although
hmpv
infect
regard
gener
mild
selflimit
adult
gain
increas
attent
caus
sever
pneumonia
howev
investig
address
outcom
aim
investig
incid
outcom
adult
patient
sever
hmpvassoci
cap
compar
patient
sever
ifvassoci
cap
studi
part
ongo
prospect
observ
cohort
studi
medic
icu
asan
medic
center
universityaffili
tertiari
care
hospit
seoul
korea
patient
age
year
admit
medic
icu
sever
cap
march
august
includ
studi
approv
institut
review
board
asan
medic
center
use
standard
protocol
investig
prospect
collect
detail
data
demograph
comorbid
medic
clinic
laboratori
find
sever
ill
score
manag
outcom
inform
microbiolog
evalu
perform
describ
previous
respiratori
virus
identifi
nasopharyng
swab
nasopharyng
aspir
bronchoscop
lavag
bal
fluid
microorgan
identifi
specimen
collect
h
hospit
admiss
consid
cap
pathogen
main
outcom
allcaus
mortal
characterist
outcom
sever
hmpvassoci
cap
patient
compar
sever
ifvassoci
cap
patient
subgroup
analys
perform
accord
presenc
absenc
immunocompromis
condit
categor
variabl
compar
use
chisquar
test
fisher
exact
test
continu
variabl
compar
use
mannwhitney
u
test
p
valu
consid
signific
analys
perform
use
spss
window
version
ibm
spss
armonk
new
york
total
patient
sever
cap
admit
medic
icu
one
pathogen
identifi
patient
overal
rhinoviru
commonli
identifi
viru
n
follow
influenza
viru
n
parainfluenza
viru
n
human
coronaviru
n
respiratori
syncyti
viru
n
hmpv
n
tabl
list
characterist
enrol
patient
median
age
hmpv
group
ifv
group
year
year
respect
diabet
mellitu
structur
lung
diseas
malign
endstag
renal
diseas
common
underli
diseas
group
diabet
mellitu
significantli
common
hmpv
group
vs
p
eleven
patient
hmpv
group
ifv
group
categor
immunocompromis
respect
p
fever
tend
common
ifv
group
p
otherwis
initi
manifest
similar
group
copathogen
less
commonli
found
hmpv
group
vs
p
detail
composit
coinfect
summar
supplementari
tabl
common
domin
radiolog
pattern
bronchopneumonia
group
vs
p
supplementari
figur
show
monthli
distribut
hmpv
ifv
case
studi
period
sever
hmpv
ifvassoci
cap
occur
predominantli
januari
june
decemb
april
respect
find
consist
observ
pattern
hmpv
ifv
incid
commun
hmpv
patient
administ
oral
ribavirin
therapi
h
administ
intraven
immunoglobulin
ivig
therapi
six
patient
administ
ivig
therapi
alon
outcom
enrol
patient
summar
tabl
supplementari
tabl
subgroup
nonimmunocompromis
patient
mortal
rate
hmpv
ifv
group
respect
p
immunocompromis
patient
mortal
rate
hmpv
ifv
group
respect
p
median
length
icu
stay
hmpv
day
vs
ifv
day
p
hospit
stay
hmpv
day
vs
ifv
day
p
significantli
differ
two
group
determin
hmpv
ifv
account
icu
admiss
sever
cap
respect
mortal
rate
sever
hmpvassoci
cap
similar
sever
ifvassoci
cap
find
show
hmpv
infect
associ
consider
incid
mortal
patient
sever
cap
mortal
data
cohort
interpret
caution
almost
patient
sever
ifvassoci
cap
receiv
antivir
therapi
either
oseltamivir
peramivir
wherea
hmpv
patient
receiv
antivir
therapi
presenc
endstag
renal
diseas
n
chronic
renal
failur
n
may
prohibit
use
ribavirin
furthermor
proven
effect
therapi
hmpv
pneumonia
oral
ribavirin
alon
combin
ivig
benefici
hmpv
patient
studi
similar
mortal
rate
two
group
despit
lack
effect
antivir
therapi
hmpv
patient
indic
virul
potenti
hmpv
might
lower
ifv
larger
control
studi
need
clarifi
effect
antivir
therapi
virul
potenti
hmpv
infect
limit
inform
avail
outcom
sever
hmpvassoci
cap
patient
recent
hwang
et
al
retrospect
analyz
risk
acut
respiratori
distress
syndrom
ard
mortal
follow
hmpv
infect
hospit
adult
inhospit
mortal
rate
among
ard
patient
similar
note
studi
includ
immunocompromis
patient
case
hospitalacquir
infect
mortal
rate
patient
analyz
separ
difficult
directli
compar
mortal
rate
result
anoth
studi
includ
hmpvposit
patient
admit
icu
overal
mortal
proport
patient
requir
mechan
ventil
lower
studi
none
prior
studi
includ
control
group
comparison
characterist
outcom
ifvassoci
pneumonia
welldocu
compar
outcom
sever
hmpvassoci
cap
ifvassoci
cap
patient
combin
ifva
ifvb
subgroup
use
control
group
analysi
outcom
ifva
ifvb
subgroup
may
differ
provid
outcom
data
group
tabl
compar
outcom
ifva
ifvb
group
differ
signific
data
shown
howev
consid
small
number
ifvb
case
issu
investig
studi
studi
sever
limit
first
perform
singl
center
limit
gener
second
adequ
number
fatal
outcom
multivari
analys
hmpv
patient
third
includ
coinfect
case
group
case
common
influenza
group
coinfect
may
affect
outcom
bia
comparison
group
fourth
case
may
includ
case
incident
upper
respiratori
tract
infect
colon
final
hmpv
genotyp
inform
viral
load
may
affect
diseas
outcom
avail
studi
conclus
incid
hmpv
infect
approxim
half
ifv
infect
patient
sever
cap
mortal
rate
sever
hmpvassoci
cap
substanti
compar
sever
ifvassoci
cap
